Skip to main content
. 2011 May 12;2(4):685–693. doi: 10.3892/etm.2011.273

Figure 2.

Figure 2.

Progression-free survival (PFS) curves according to pre-treatment serum levels of a combination of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) according to histologic type. (a) Patients with l-CEA and h-CYFRA 21-1, (b) patients with l-CEA and l-CYFRA 21-1 or h-CEA and h-CYFRA 21-1 and (c) patients with h-CEA and l-CYFRA 21-1. (A) Patients with adenocarcinoma. (B) Patients with squamous cell carcinoma.